Database Query Results : Ginkgo biloba, ,

Gb, Ginkgo biloba: Click to Expand ⟱
Features:
Ginkgo biloba from an ancient tree.
Ginkgo biloba leaf extracts (commonly standardized as EGb 761, ~24% flavonol glycosides and ~6% terpene lactones) are best known for antioxidant, anti-inflammatory, platelet-activating factor (PAF) antagonism, and neurovascular effects. In preclinical cancer models, Ginkgo constituents have been associated with modulation of NF-κB, Nrf2, MAPK, and PI3K/AKT pathways, along with effects on cell cycle, apoptosis, and angiogenesis. Clinical oncology evidence is limited and heterogeneous. Important safety considerations include antiplatelet effects (bleeding risk) and CYP/P-gp interactions (product- and dose-dependent).

-Ginkgo can inhibit platelet aggregation

-Scavenges free radicals; reduces oxidative stress in neuronal cells -Suppresses pro-inflammatory cytokines (e.g., TNF-α, IL-1β).
-Enhances microcirculation and oxygen delivery to brain tissues.
-Reduces Aβ plaque formation and associated neurotoxicity.
-May improve memory, attention, and processing speed in early-stage AD.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Antioxidant systems (Nrf2/ARE; SOD, GSH) Stress adaptation modulation (context-dependent) Nrf2 ↑; antioxidant enzymes ↑; oxidative injury ↓ R, G Redox buffering Flavonol glycosides commonly activate antioxidant defenses; direction in tumors is model-dependent.
2 NF-κB inflammatory transcription NF-κB ↓; cytokines/COX-2 ↓ (reported) Inflammation tone ↓ R, G Anti-inflammatory signaling Preclinical studies report NF-κB modulation; strength varies by constituent and dose.
3 PAF receptor antagonism (ginkgolides) Pro-tumor inflammatory signaling ↓ (context) Platelet activation ↓; microcirculation effects P, R Lipid mediator antagonism Ginkgolides are PAF antagonists; clinically relevant for antiplatelet/vascular effects.
4 PI3K → AKT (± mTOR) survival axis PI3K/AKT modulation (reported; model-dependent) ↔ R, G Growth/survival modulation Observed in some tumor models; best described as reported/context-dependent.
5 MAPK re-wiring (ERK / JNK / p38) MAPK modulation (context-dependent) ↔ P, R, G Stress/mitogenic signaling adjustment Directions vary by extract composition and cell type.
6 Cell-cycle control (Cyclins/CDKs) Cell-cycle arrest ↑ (reported) ↔ G Cytostasis Reported in vitro; typically downstream of signaling changes.
7 Intrinsic apoptosis (mitochondrial/caspase linked) Apoptosis ↑ (reported) ↔ G Cell death execution Seen in selected cancer cell lines; not a universal cytotoxin signature.
8 Angiogenesis signaling (VEGF & related) Angiogenic outputs ↓ (reported) ↔ G Anti-angiogenic phenotype Phenotype-level outcomes in some models; strength varies.
9 Drug metabolism / transport (CYPs, P-gp) Potential interaction with chemo agents (context) CYP/P-gp modulation (product- and dose-dependent) R, G Interaction constraint Reports of CYP (e.g., CYP2C19/3A4) and P-gp modulation are mixed; interaction risk depends on extract and dose.
10 Safety constraint (antiplatelet / bleeding risk) — Platelet aggregation ↓; bleeding risk ↑ (context) — Clinical risk management PAF antagonism and antiplatelet effects warrant caution with anticoagulants/antiplatelets and perioperatively.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid receptor/mediator interactions; early redox shifts)
  • R: 30 min–3 hr (acute signaling and transcription changes)
  • G: >3 hr (gene-regulatory adaptation and phenotype outcomes)
Ginkgo biloba — Alzheimer’s Disease (AD) Mechanism Table
Rank Pathway / Axis AD / Neural Context TSF Primary Effect Notes / Interpretation
1 Oxidative stress reduction (Nrf2/ARE; SOD, GSH) Oxidative injury ↓; lipid peroxidation ↓ R, G Neuroprotection via redox buffering Flavonol glycosides enhance endogenous antioxidant defenses and reduce oxidative stress, a core driver in AD pathology.
2 Mitochondrial protection ATP production stabilization; mitochondrial membrane integrity ↑ P, R Energy support EGb 761 has been reported to protect mitochondrial function and reduce ROS generation in neuronal models.
3 Neuroinflammation (NF-κB; microglial activation) Microglial activation ↓; pro-inflammatory cytokines ↓ R, G Anti-inflammatory neuroprotection Reduction of neuroinflammatory signaling may contribute to slowed neurodegenerative processes.
4 Platelet-activating factor (PAF) antagonism Improved cerebral microcirculation; reduced inflammatory mediator activity P Vascular support Ginkgolides act as PAF antagonists; improved cerebral blood flow may support cognition in vascular/mixed dementia.
5 β-amyloid aggregation modulation Aβ aggregation ↓ (reported in vitro) G Protein aggregation modulation Preclinical studies suggest interference with Aβ toxicity and aggregation; clinical relevance remains uncertain.
6 Synaptic plasticity / neurotransmission Cholinergic tone modulation (reported); synaptic resilience ↑ G Cognitive support Some evidence suggests improved synaptic function and neurotransmission in aging models.
7 Apoptosis suppression (neuronal survival) Pro-apoptotic signaling ↓ (reported) G Neuronal preservation Reduction of caspase activation and mitochondrial apoptotic signaling has been reported in neuronal injury models.
8 Clinical cognitive outcomes Modest cognitive benefit in mild-to-moderate dementia (mixed results) — Symptom-level effect Some randomized trials suggest small improvements in cognition or activities of daily living; others show limited effect. Benefit appears modest.
9 Safety constraint (antiplatelet effect) Bleeding risk ↑ in susceptible patients — Clinical risk management PAF antagonism and platelet aggregation inhibition require caution with anticoagulants and perioperative settings.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid receptor and mitochondrial interactions)
  • R: 30 min–3 hr (acute inflammatory and redox signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
Scientific Papers found: Click to Expand⟱
1117- Gb,    Ginkgobiloba leaf extract mitigates cisplatin-induced chronic renal interstitial fibrosis by inhibiting the epithelial-mesenchymal transition of renal tubular epithelial cells mediated by the Smad3/TGF-β1 and Smad3/p38 MAPK pathways
- vitro+vivo, Kidney, HK-2
α-SMA↓, COL1↓, TGF-β↓, SMAD2↓, SMAD3↓, p‑SMAD2↓, p‑SMAD3↓, p38↓, p‑p38↓, Vim↓, TIMP1↓, CTGF↓, E-cadherin↑, MMP1:TIMP1↑,
1186- Gb,    Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis
- in-vitro, PC, NA - in-vitro, Nor, HUVECs - in-vivo, PC, NA
tumCV↓, *toxicity∅, TumCMig↓, TumCI↓, Apoptosis↑, AMPK↑, lipoGen↓, ACC↓, FASN↓,
1187- Gb,    Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase
- in-vitro, Melanoma, U251 - in-vitro, Melanoma, MM.1S
STAT3↓, PTEN↑, Apoptosis↑, PTPN6↑,
1188- Gb,    The potential of Ginkgo biloba in the treatment of human diseases and the relationship to Nrf2-mediated antioxidant protection
- Review, NA, NA
*NRF2↑, *ROS↓,
1189- Gb,    New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer
- Review, NA, NA
Apoptosis↑, TumCP↓, TumCI↓, TumCMig↓, Inflam↓, antiOx↑, angioG↓,
1190- Gb,    Extract of Ginkgo biloba exacerbates liver metastasis in a mouse colon cancer Xenograft model
- in-vivo, CRC, SW-620
TumMeta↑, Ki-67↑,
3721- Gb,    Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice
- Review, AD, NA
*antiOx↑, *ROS↓, *SOD↑, *Catalase↑, *GSR↑, *MMP↑, *Inflam↓, *Aβ↓, *memory↑, *Dose↝, *BBB↑, *neuroP↑,
3722- Gb,    Alzheimer's disease: Research summaries – Do Ginkgo products help?
- Review, AD, NA
*memory↑, *AntiAg↑,
3723- Gb,    Can We Use Ginkgo biloba Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
- Review, AD, NA
*memory↑, *antiOx↑, *Casp3↓, *APP↓, *AChE↓, *Aβ↓, *5HT↑, *SOD↓, *MDA↓, *NO↓, *GSH↑, *Bcl-2↑, *BAX↑, *TNF-α↓, *IL1β↑, *iNOS↓, *IL10↓, *p‑tau↓, *ROS↓, *MAOB↓, *cognitive↑, *neuroP↑, *Apoptosis↓,
4244- Gb,    Effects of Six-Week Ginkgo biloba Supplementation on Aerobic Performance, Blood Pro/Antioxidant Balance, and Serum Brain-Derived Neurotrophic Factor in Physically Active Men
- Human, Nor, NA
*BDNF∅,
4245- Gb,    Standardized extract of Ginkgo biloba enhances memory persistence over time
- in-vivo, NA, NA
*memory↑, *BDNF↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   AMPK↑, 1,   FASN↓, 1,   lipoGen↓, 1,  

Cell Death ⓘ

Apoptosis↑, 3,   p38↓, 1,   p‑p38↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

PTEN↑, 1,   PTPN6↑, 1,   STAT3↓, 1,  

Migration ⓘ

COL1↓, 1,   CTGF↓, 1,   E-cadherin↑, 1,   Ki-67↑, 1,   MMP1:TIMP1↑, 1,   SMAD2↓, 1,   p‑SMAD2↓, 1,   SMAD3↓, 1,   p‑SMAD3↓, 1,   TGF-β↓, 1,   TIMP1↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 1,   TumMeta↑, 1,   Vim↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Clinical Biomarkers ⓘ

Ki-67↑, 1,  
Total Targets: 32

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GSH↑, 1,   GSR↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 3,   SOD↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   BAX↑, 1,   Bcl-2↑, 1,   Casp3↓, 1,   iNOS↓, 1,  

Migration ⓘ

AntiAg↑, 1,   APP↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↓, 1,   IL1β↑, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   AChE↓, 1,   BDNF↑, 1,   BDNF∅, 1,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,   MAOB↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   memory↑, 4,   neuroP↑, 2,   toxicity∅, 1,  
Total Targets: 35

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:89  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page